Moderna Inc./ US60770K1079 /
2024-05-23 7:16:13 PM | Chg. +3.8600 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
151.7200EUR | +2.61% | 328 Turnover: 49,309.2400 |
151.6000Bid Size: 200 | 151.8600Ask Size: 200 | 58.12 bill.EUR | - | - |
GlobeNewswire
05-22
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn an...
GlobeNewswire
05-12
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
05-02
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-01
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-04
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Aga...
GlobeNewswire
03-04
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024